GIP and asthma: In summary, GLP-1 (and possibly GIP/GLP-1) receptor agonists could improve asthma outcomes through weight reduction, decreased airway inflammation and mucus secretion, decreased type 2 inflammation signaling, reduction in IL-4, 5, 13, and 33 secretion, reduced mast cell activity, as well as increases in surfactant production and smooth muscle relaxation [57].